Starting with a "Universal" Influenza vaccine
Employees: 11-50
Total raised: $19.01M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Start Capi... | start-capi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.03.2025 | Series B | $10M | - |
| 10.07.2019 | Series A | $9.01M | - |
Mentions in press and media 8
| Date | Title | Description |
| 12.03.2025 | Osivax: €10 Million Raised For Developing Vaccines To Provide Protection Against Respiratory Viruses | Osivax – a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses – announced the first closing of its Series B financing, raising €10 million from new and existing inv... |
| 04.03.2025 | Osivax Raises $10M in First Close of Series B Funding | Osivax, a Lyon, France-based biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, closed its Series B financing, raising €10M from new and existing investors. Backer... |
| 10.07.2019 | Osivax raises €8M for universal flu vaccine clinical trials | Osivax has raised €8 million ($9 million) to take a universal flu vaccine candidate through early-phase development. The series A round comes as Osivax nears the delivery of phase 1 data on a candidate that achieved widespread protection in... |
| 10.07.2019 | Lyon-based biotech startup Osivax raises €8 million to develop novel, universal flu vaccines | Lyon–based biotech startup Osivax was founded in 2017 to develop a universal flu vaccine that will be effective year after year, despite mutations of the virus. The startup has just raised €8 million in financing led by Noshaq, a Belgian in... |
| 10.07.2019 | French biotech startup Osivax secures €8M to develop universal vaccine against influenza | A biotech startup from France, Osivax announced today that it has secured €8 million of financing through a Series A financing round to fund further progress in the clinical development of its lead flu vaccine candidate and to support strat... |
| 10.07.2019 | Osivax raises €8M for universal flu vaccine clinical trials | Osivax has raised €8 million ($9 million) to take a universal flu vaccine candidate through early-phase development. The series A round comes as Osivax nears the delivery of phase 1 data on a candidate that achieved widespread protection in... |
| 10.07.2019 | Osivax Raises €8M in Series A Funding | Osivax, a Lyon, France-based developer of a universal flu vaccine, secured €8m in Series A financing. The round, which brought total funding raised to date to €11m, including its seed financing from Pradeyrol Développement and other family ... |
| - | Osivax | - |